insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study.

NPJ precision oncology 2026 Vol.10(1) p. 70

Nakamura Y, Reiter JG, Natarajan P, Babiarz J, Srinivasan P, Joshi J, Lin Y, Chen TC, Liang N, Maw S, Haghshenas E, Kushwaha G, Gutman B, Tunc I, Chan WC, Tin A, Huang Y, Bristow SL, Malhotra M, Sharma S, Sanchez SA, Jurdi A, Liu MC, Kawli T, Rabinowitz M, Aleshin A, Kotani D, Eiji O, Yoshino T

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

This study validates a methylation-based, tissue-free assay (Latitude assay) for detecting molecular residual disease (MRD) in colorectal cancer (CRC), analyzing data from 195 patients (1230 timepoint

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P < 0.001
  • HR 10.0
  • Sensitivity 58.5%

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Nakamura Y, Reiter JG, et al. (2026). Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study.. NPJ precision oncology, 10(1), 70. https://doi.org/10.1038/s41698-026-01277-5
MLA Nakamura Y, et al.. "Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study.." NPJ precision oncology, vol. 10, no. 1, 2026, pp. 70.
PMID 41555007
DOI 10.1038/s41698-026-01277-5

Abstract

This study validates a methylation-based, tissue-free assay (Latitude assay) for detecting molecular residual disease (MRD) in colorectal cancer (CRC), analyzing data from 195 patients (1230 timepoints) from the observational GALAXY study. The assay demonstrated that ctDNA-positivity correlated with significantly worse disease-free survival (DFS) in both the MRD (HR = 10.0, P < 0.001) and post-definitive treatment surveillance windows (HR = 31.9, P < 0.001). In the MRD window, the assay demonstrated a sensitivity of 58.5% (38/65), while the specificity in patients who did not receive adjuvant chemotherapy (ACT) was 100% (63/63). Longitudinally, relapse was detected with a sensitivity of 84.4% (54/64), with high specificity at the patient (92.1%; 116/126) and sample (97.2%; 619/637) levels. Median lead time from first circulating tumor DNA (ctDNA)-positive result to relapse was 4.6 months. For high-risk stage II and III CRC, ctDNA-positive patients benefited from ACT (adj.HR = 0.014, P < 0.0001), unlike ctDNA-negative patients. These findings highlight the robust prognostic and predictive capabilities of this tissue-free MRD assay in CRC patients.

같은 제1저자의 인용 많은 논문 (5)